A novel dual CCK/ GLP-1 receptor agonist ameliorates cognitive impairment in 5 × FAD mice by modulating mitophagy via the PINK1/Parkin pathway

Apr 4, 2025International immunopharmacology

A new drug targeting CCK and GLP-1 receptors improves memory in Alzheimer's mice by adjusting cell cleanup through the PINK1/Parkin pathway

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

The novel dual CCK/GLP-1 receptor agonist improved cognitive deficits in a mouse model of Alzheimer's disease.

Cognitive performance improved in 5 × FAD mice treated with the dual CCK/GLP-1 receptor agonist.
The treatment reduced amyloid-beta accumulation in the brain.
Mitochondrial damage was alleviated through the induction of mitophagy.
In an in vitro model, the dual CCK/GLP-1 receptor agonist showed neuroprotective effects by regulating the PINK1/Parkin-mediated mitophagy process.
The new CCK/GLP-1 receptor agonist outperformed the GLP-1 analogue liraglutide in certain indicators.

AI simplified

To date, no therapeutic drugs available on the market can effectively reverse the progression of Alzheimer's disease (AD). Although Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and Cholecystokinin (CCK) RAs have shown some promise in AD research, little is known about the neuroprotective effects of a novel dual CCK/GLP-1 RA in AD. This study sought to examine the effects of the novel dual CCK/GLP-1 RA on cognitive performance in an AD mouse model and to explore the associated mechanisms. Our findings indicate that dual CCK/GLP-1 RA improved cognitive deficits, reduced amyloid-beta (Aβ) accumulation, and alleviated mitochondrial damage in 5 × FAD mice by inducing mitophagy. In an in vitro model of AD cells induced by Aβ, CCK/GLP-1 RA could exert neuroprotective effects by regulating PINK1/Parkin-mediated mitophagy. These data reveal for the first time that the new CCK/GLP-1 RA modulates mitophagy via PINK1/Parkin pathway and enhances cognitive function in the 5 × FAD animal model. Moreover, the performance of the CCK/GLP-1 RA in certain indicators was superior to that of GLP-1 analogue liraglutide, suggesting that it may represent a more promising therapeutic option for AD.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

A novel dual CCK/ GLP-1 receptor agonist ameliorates cognitive impairment in 5 × FAD mice by modulating mitophagy via the PINK1/Parkin pathway

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief